• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by IMAC Holdings Inc.

    5/20/25 4:30:23 PM ET
    $BACK
    Medical Specialities
    Health Care
    Get the next $BACK alert in real time by email
    false 0001729944 0001729944 2025-05-16 2025-05-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 16, 2025

     

    IMAC Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38797   83-0784691

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    3401 Mallory Lane, Suite 100

    Franklin, Tennessee

      37067
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (844) 266-4622

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   BACK   OTC Markets Group, Inc.

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 4.02 Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review.

     

    On May 16, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of the Company, in consultation with management, concluded that the following previously issued consolidated financial statements of the Company should no longer be relied upon and need to be restated because of a non-cash error in accounting for its preferred dividends:  (1) the financial statements pertaining to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024, (2) the financial statements pertaining to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 and (3) the financial statements pertaining to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

     

    The Company is currently assessing the impact of the error on its financial statements and is working to amend each quarterly or annual report as needed.

     

    The errors described above are not related to the Company’s cash position and stem from a material weakness in the Company’s internal control over financial reporting (“ICFR”). This material weakness is attributed to the Company not having sufficient resources within its accounting department to address complex financial instruments in the consolidated financial statements, as previously concluded by management in Item 9A of the Form 10-K.

     

    The Audit Committee and management have discussed the matters disclosed in this Form 8-K with Marcum LLP, the Company’s independent registered public accounting firm.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: May 20, 2025

     

      IMAC HOLDINGS, INC.
         
      By: /s/ Faith Zaslavsky
      Name: Faith Zaslavsky
      Title: Chief Executive Officer

     

     

     

    Get the next $BACK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BACK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BACK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

      Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab (Keytruda®) compared to PD-L1 at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference. The study, conducted with I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies – including the one most commonly used as a companion diagnostic – yet only MHC-II expression showed a statistically significant correlation with patient outcomes. "Although PD-L1 testing is standard in some cases, many pati

      2/24/25 8:15:00 AM ET
      $BACK
      Medical Specialities
      Health Care
    • Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

      Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink Technologies, Inc. – to Ignite Proteomics LLC. The AMA CPT code is listed on the Medicare Clinical Laboratory Fee Schedule (CLFS) and is addressed by the Palmetto GBA MolDx "Proteomics Testing" article (A59636). This milestone integrates both the laboratory capability and the owned and licensed intellectual property of the proteomic breast cancer assay into Ignite Proteomics. PLA codes like 0249U are essential building blocks for new diagnostics, as

      2/19/25 9:15:00 AM ET
      $BACK
      Medical Specialities
      Health Care
    • Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

      The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), announces the publication of a significant study in the British Journal of Cancer titled "Functional activation of the AKT–mTOR signalling axis in a real-world metastatic breast cancer cohort". This research underscores the critical importance of measuring functional protein activation within the AKT–mTOR signaling pathway to accurately predict patient responses to targeted cancer therapies. Advancing Precision Oncology Through Direct Protein Activation Measu

      2/10/25 9:15:00 AM ET
      $BACK
      Medical Specialities
      Health Care

    $BACK
    SEC Filings

    See more
    • IMAC Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement

      8-K - IMAC Holdings, Inc. (0001729944) (Filer)

      6/18/25 4:49:24 PM ET
      $BACK
      Medical Specialities
      Health Care
    • IMAC Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement

      8-K - IMAC Holdings, Inc. (0001729944) (Filer)

      6/6/25 5:08:52 PM ET
      $BACK
      Medical Specialities
      Health Care
    • IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Leadership Update, Financial Statements and Exhibits

      8-K - IMAC Holdings, Inc. (0001729944) (Filer)

      6/5/25 5:25:00 PM ET
      $BACK
      Medical Specialities
      Health Care

    $BACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 5 filed by Ruiz Jorge

      5 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/18/25 12:03:25 PM ET
      $BACK
      Medical Specialities
      Health Care
    • Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

      4 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/18/25 12:01:15 PM ET
      $BACK
      Medical Specialities
      Health Care
    • Large owner Ruiz Jorge sold $15,000 worth of shares (5,000 units at $3.00), decreasing direct ownership by 3% to 141,229 units (SEC Form 4)

      4 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/18/25 11:59:00 AM ET
      $BACK
      Medical Specialities
      Health Care

    $BACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

      4 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/18/25 12:01:15 PM ET
      $BACK
      Medical Specialities
      Health Care
    • Large owner Ruiz Jorge bought $590,192 worth of shares (164,872 units at $3.58) and sold $39,955 worth of shares (16,487 units at $2.42) (SEC Form 4)

      4 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/14/25 3:43:49 PM ET
      $BACK
      Medical Specialities
      Health Care